Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Strategy
      • Orphan Drugs
    • Board
    • Team
    • Partners
    • Relevant publications
  • Mitochondrial Diseases
    • Primary mitochondrial diseases
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
    • Partnering
      • BD Contact
  • Investors
    • Financial reports
      • Annual reports
      • Interim reports
      • Other financial information
    • Financial Calendar
    • Share and owner information
    • Equity research
    • Corporate governance
      • General meeting
      • General meetings archive
    • IR contact
  • News
    • Press releases
    • Newsletters
    • Events and Presentations
      • World Mitochondrial Disease Week 2022
      • World Mitochondrial Disease Week 2021
    • Company Calendar
    • News subscription
    • Press photos
    • Media contact
    • Privacy policy
  • Contact

Press releases

  • All
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
22 February, 2022
Regulatory

Abliva AB Year-End Report January – December 2021

"2021 was a defining year for Abliva, focused on portfolio delivering, de-risking our assets and building relationships as we prepared for success in 2022." - Ellen Donnelly, CEO
Continue reading
19 February, 2021
Regulatory

Abliva AB Year-End Report January – December 2020

2020 summary
Continue reading
19 February, 2020
Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2019

Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVi ...
Continue reading
28 February, 2019
Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2018

Positioned for clinical progress
Continue reading
20 February, 2018
Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2017

Strong trend for mitochondrial disorder projects
Continue reading
21 February, 2017
Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2016

Important steps forward and new research collaborations
Continue reading
19 February, 2016
Regulatory

NeuroVive: Year-End Report 1 Jan. 2015 – 31 Dec. 2015

Fourth Quarter (1 Oct. 2015 - 31 Dec. 2015) · Net revenues were SEK 0 (0) and other operating income was SEK 23,000 (8,000). · Loss before tax was SEK -7,366,000 (-17,346,000). · Earnings per share* w ...
Continue reading
18 February, 2015
Regulatory

NeuroVive: Year-End Report 1 Jan. 2014 till 31 Dec. 2014

Fourth Quarter (1 Oct. 2014 - 31 Dec. 2014) · Net revenues were SEK 0 (0) and other operating income was SEK 8,000 (12,000). · Loss before tax was SEK -17,346,000 (9,169,000). · Earnings per share* we ...
Continue reading
19 February, 2014
Regulatory

NeuroVive: Year-End Report 1 Jan. 2013 till 31 Dec. 2013

NeuroVive consolidates positioning as leading mitochondrial medicine company
Continue reading

Popular shortcuts

Research & Development
Investors
Primary mitochondrial diseases
Interim reports

Receive updates straight to your inbox

Choose the categories that you are interested in, and check preferred language.

  1. Startpage

This is Abliva

  • Strategy
  • Board
  • Team
  • Partners and advisers
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • Partnering
  • BD Contact

Investors

  • Investors
  • Annual reports
  • Interim reports
  • Other financial information
  • Financial Calendar
  • Share and owner information
  • Equity research
  • Corporate governance
  • General meeting
  • General meetings archive
  • IR contact

News

  • Press releases
  • Newsletters
  • Events and Presentations
  • Capital Markets Day 2020
  • Mitochondria Day 2020
  • News subscription
  • Press photos
  • Media contact
  • Privacy policy

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all